Skip to content

Molecular Psychiatry

ISSN 1476-5578, 1359-4184

119 papers in the library · 4,421 citations · publishing 2005-2026

Papers

Sort Most recent Most cited

Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use

Molecular Psychiatry April 8, 2026 Johannes G. Ramaekers, Kim P. C. Kuypers, Franz X. Vollenweider 1 citation

MDMA's history spans military experimentation, recreational use, and clinical trials for PTSD treatment, reflecting both promise and controversy. While studies in heavy users suggested possible neurotoxicity, evidence remains inconclusive. Clinical trials show that one to three sessions of MDMA-assisted psychotherapy can alleviate PTSD symptoms, yet regulators have criticized inadequate...

DOI: 10.1038/s41380-026-03602-7 (opens in new tab) Full text (opens in new tab) Neurocognitive Profiling computer programming Medline Clinical trial +2

Adenosine surges: A step forward in understanding antidepressant actions of ketamine

Molecular Psychiatry April 8, 2026 Daniel Dautan, Anderson Camargo, Per Svenningsson

The discovery that a single subanesthetic dose of (R,S)-ketamine induces rapid and long-lasting antidepressant effects by a completely different mechanism represents one of the most substantial break-throughs in depression pharmacotherapy. The recent study in Nature by Yue and colleagues represents a signi fi cant conceptual and technical advance by identifying NMDA-independent transient...

Standardized chronic restraint stress protocols reveal dynamic evolution of behavioral adaptations in male mice: implications for translational neuroscience.

Molecular Psychiatry April 1, 2026 Zijian Lv, Qifeng Xie, Kecan Li et al. 3 citations

Chronic stress induces neurobiological adaptations that manifest as altered behavioral patterns in both humans and animal models. To enhance the translational value of preclinical research, we systematically evaluated chronic restraint stress (CRS) protocols in mice through longitudinal tracking of behavioral outcomes across multiple validated assays. By comparing various CRS parameters, we...

Psilocybin mitigates chronic behavioral and neurobiological alterations in a rat model of recurrent intimate partner violence-related brain injury.

Molecular Psychiatry April 1, 2026 Josh Allen, Mujun Sun, Tamara L Baker et al. 1 citation

Intimate partner violence (IPV) poses a significant medical concern, predominantly affecting females. IPV-related brain injuries (IPV-BI), such as mild traumatic brain injury (mTBI) and non-fatal strangulation (NFS), sustained during physical attacks are common and often repetitive. Chronic neurobehavioral sequalae from IPV-BI are associated with neuroinflammation and impaired neuroplasticity,...

Spatiotemporal complexity in the psychotic brain.

Molecular Psychiatry April 1, 2026 Qiang Li, Jingyu Liu, Godfrey D Pearlson et al.

Psychotic disorders, such as schizophrenia and bipolar disorder, pose significant diagnostic challenges with major implications on mental health. The measures of resting-state fMRI spatiotemporal complexity offer a powerful tool for identifying irregularities in brain activity. To capture global brain connectivity, we employed information-theoretic metrics, overcoming the limitations of...

The dynamics of AMPA receptors underlies the efficacy of ketamine in treatment resistant patients with depression

Molecular Psychiatry March 5, 2026 Waki Nakajima, Mai Hatano, Yohei Ohtani et al. 1 citation

Approximately 30% of patients with depression suffer from treatment-resistant depression (TRD). Ketamine has shown antidepressant efficacy for TRD. While glutamate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) has been demonstrated to play crucial roles in the process of pharmacological action of ketamine in experimental animals, it remains elusive how ketamine exhibits...

Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors

Molecular Psychiatry March 1, 2026 Tyler G. Ekins, Chloe Rybicki-Kler, Tao Deng et al. 9 citations

Classical psychedelic drugs show promise as a treatment for major depressive disorder and related psychiatric disorders. This therapeutic efficacy stems from long-lasting psychedelic-induced neuroplasticity onto prefrontal cortical neurons and is thought to require the postsynaptic expression of serotonin 2A receptors (5-HT_2AR). However, other cortical regions such as the granular...

The mPFC molecular clock mediates the effects of sleep deprivation on depression-like behavior and regulates sleep consolidation and homeostasis

Molecular Psychiatry March 1, 2026 Wilf Gardner, David H. Sarrazin, Martin Balzinger et al.

Disruptions in sleep, circadian rhythms, and neural plasticity are closely linked to the pathophysiology and treatment of depression. Acute sleep deprivation (SD) produces rapid but transient antidepressant effects, yet the underlying mechanisms remain poorly understood. Using a mouse model of stress-induced depression, we found altered sleep architecture, impaired sleep homeostasis, and...

Sex differences in placebo and antidepressant response to intranasal esketamine for treatment-resistant depression

Molecular Psychiatry February 18, 2026 Marie Huc, Sara Siddiqi, Mysa Myers et al. 1 citation

Esketamine has emerged as a fast-acting antidepressant option for individuals with treatment-resistant depression (TRD). Yet, little is known about how sex-assigned-at-birth shapes symptom-specific responses to these interventions, a critical gap in the move toward precision psychiatry. To address this gap, we conducted a pooled analysis of five randomized, double-blind, placebo-controlled...

Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice

Molecular Psychiatry February 12, 2026 Sixtine Fleury, Katherine M. Nautiyal correction

should have read "Overall, our research implicates the 5-HT1BR, a nonhallucinogenic serotonin receptor, as a potential mediator of the behavioral and neural effects of psilocybin in mice."The final sentence of the Introduction should have read "Our findings suggest that the 5-HT1BR influences brain-wide neural changes following psilocybin administration and may contribute to its enduring...

Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin

Molecular Psychiatry February 3, 2026 Pablo Mallaroni, S. Parker Singleton, Natasha L. Mason et al.

As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored for specific populations. 2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenethylamine reported to produce less dysphoria and subjective impairment than the psychedelic tryptamine psilocybin. Despite its popularity among recreational...

Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.

Molecular Psychiatry December 1, 2025 Ross J. Purple, Rahul Gupta, Christopher W. Thomas et al. correction

In this article the author’s name Robin Carhart-Harris was incorrectly written as Robin Carhartt-Harris. The original article has been corrected.

Exploring the therapeutic potential of psychedelics in treating substance use disorders.

Molecular Psychiatry December 1, 2025 Yuanpeng Li, Hongyuan Li, Hongshuang Wang et al.

Psychedelics, particularly psilocybin, have garnered significant attention as potential therapeutic tools for treating substance use disorders (SUDs), such as those related to alcohol, nicotine, heroin (an opioid), or cocaine. Traditional treatments often fall short, leading to high relapse rates and an urgent need for innovative approaches. This article explores the emerging role of...

Quantitative monitoring of ketamine's impact on synaptic density using 11C-UCB-J PET imaging in the corticosterone mouse model of anxiety/depression.

Molecular Psychiatry November 18, 2025 Cassandre Corvo, Sébastien Goutal, Indira Mendez-David et al. 1 citation

Ketamine was shown to promote synaptogenesis, which is thought to account for its antidepressant effects through the restoration of lost synaptic connections observed in depression. PET imaging using 11C-UCB-J, a radiotracer targeting the synaptic vesicle protein 2 A (SV2A), was investigated as a translational method to monitor ketamine-induced changes in synaptic density in the corticosterone...

DOI: 10.1038/s41380-025-03369-3 (opens in new tab) Full text (opens in new tab) Ketamine ketamine Single ketamine dose Repeated doses Neuroplasticity brain connections +14

Ketamine reduces microglial activation and brain monocyte infiltration and promotes peripheral regulatory immune cells, relieving lipopolysaccharide (LPS)-induced depressive-like behavior in mice.

Molecular Psychiatry November 18, 2025 A. Arena, M. R. Rubinstein, A. M. Genaro et al.

Ketamine has emerged as a rapid and sustained treatment for Major Depressive Disorder (MDD) and an alternative for patients who have not responded to traditional therapies. Its effects have been partly attributed to the noncompetitive antagonism of the N-methyl-D-aspartate receptor (NMDAR) in the central nervous system, which enhances neuroplasticity. However, the etiopathology of MDD is...

The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents

Molecular Psychiatry November 14, 2025 Núria Nadal‐gratacós, Pol Puigseslloses, Laura Hernández‐guzmán et al.

Psychedelics have garnered significant interest for their therapeutic potential in mental health conditions such as depression, anxiety, and post-traumatic stress disorder. While research has primarily focused on well-studied psychedelics, phenethylamine derivatives have also gathered interest for their potential therapeutic applications. Thus, this study aims to investigate the pharmacological...

DOI: 10.1038/s41380-025-03341-1 (opens in new tab) Full text (opens in new tab) Phenethylamine Antidepressant Dopamine Reboxetine +8

The 4-alkyl chain length of 2,5-dimethoxyamphetamines differentially affects in vitro serotonin receptor actions versus in vivo psychedelic-like effects

Molecular Psychiatry November 5, 2025 Dino Luethi, Grant C. Glatfelter, Eline Pottie et al. 1 citation

Abstract Various ring-substituted α-methylphenethylamines (i.e., amphetamines) produce psychedelic-like effects that are primarily mediated by activity at 5-hydroxytryptamine 2A (5-HT 2A ) receptors. Small lipophilic substituents at the 4-position of the 2,5-dimethoxyamphetamine core structure can greatly enhance the clinical potency of such derivatives. Here, we studied the effects of various...

Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential

Molecular Psychiatry October 21, 2025 Pol Puigseslloses, Núria Nadal‐gratacós, Berta Fumàs et al. 1 citation

Current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRI), often present a delayed onset of action and fail to effectively treat a large proportion of patients, leaving a gap in the treatment of mood disorders. Psychedelics have recently emerged as promising alternatives due to their ability to produce fast-acting antidepressant effects through neuroplastic...

The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health.

Molecular Psychiatry September 30, 2025 Xiubo Du, Jiantao Liu, Xiaohui Wang 2 citations

Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ketamine, and N,N-dimethyltryptamine (DMT), have captured the attention of scientists, artists, and seekers alike for their profound ability to alter consciousness and inspire creativity. The concept of "creation" encompasses multiple interpretations-ranging from generating novel ideas to fostering personal transformation. This...

Psychedelic studies in nonhuman primates: Past and future.

Molecular Psychiatry September 12, 2025 Jamie C. Masthay, Alex C. Kwan, Steve W. C. Chang

Studies of serotonergic or 'classic' psychedelics in nonhuman primates (NHPs) have provided valuable information about the drugs' effects on the brain and behavior in closely related species to humans. Psychedelics induce characteristic changes to both spontaneous and operant behaviors in NHPs, though variability exists in the different effects reported by different studies; this variability...

Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin

Molecular Psychiatry August 26, 2025 Ross J. Purple, Rahul Gupta, Christopher W. Thomas et al. 2 citations

Abstract We quantify cellular- and circuit-resolution neural network dynamics following therapeutically relevant doses of the psychedelic psilocybin. Using chronically implanted Neuropixels probes, we recorded local field potentials (LFP) alongside action potentials from hundreds of neurons spanning infralimbic, prelimbic and cingulate subregions of the medial prefrontal cortex of...

Above the threshold, beyond the trip: the role of the 5-HT2A receptor in psychedelic-induced neuroplasticity and antidepressant effects

Molecular Psychiatry August 23, 2025 Adam J. Drewko, Ron L. P. Habets, Tibor M Brunt 4 citations

Serotonergic psychedelics, including the recreationally used psilocybin and LSD, have become promising therapeutic agents for the treatment of treatment-resistant depression. While it is generally agreed that they exhibit their antidepressant effects by inducing rapid and sustained neuroplasticity, the molecular mechanisms responsible are widely debated. In particular, the role of the serotonin...

DOI: 10.1038/s41380-025-03169-9 (opens in new tab) Neuroplasticity Antidepressant Vortioxetine Psychotherapist +1

The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.

Molecular Psychiatry July 7, 2025 Dongsun Park, Gwangho Lee, Won-Gyu Lee et al. 7 citations

Major depressive disorder is a debilitating condition, with many patients unresponsive to conventional monoaminergic antidepressants. Rapid-acting antidepressants such as ketamine and psilocybin offer promising alternatives, relieving symptoms within hours. Ketamine, an NMDA receptor antagonist, and psilocybin, a serotonergic psychedelic primarily targeting 5-HT2A receptors, both enhance...

Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.

Molecular Psychiatry July 1, 2025 Rebecca Harding, Neomi Singer, Matthew B. Wall et al. correction

The following part of the abstract had a minor error: ‘Following PT, there was greater activation in the ventromedial prefrontal cortex and sensory regions, and reduced activation in the angular gyrus.’ This is now corrected to ‘Following PT, there was decreased activation in the ventromedial prefrontal cortex and angular gyrus, and greater activation in sensory regions.’ The original article...

DOI: 10.1038/s41380-025-03066-1 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Depression treatment Mood improvement Mental health therapy +22

Psilocybin increases emotional empathy in patients with major depression.

Molecular Psychiatry June 1, 2025 Johannes Jungwirth, Robin von Rotz, Isabel Dziobek et al. 19 citations

Empathy plays a crucial role in interpersonal relationships and mental health. It is decreased in a variety of psychiatric disorders including major depression. Psilocybin, a promising candidate for treating depression, has been shown to acutely increase emotional empathy in healthy volunteers. However, no study has investigated this effect and its relevance for symptom improvement in a...

DOI: 10.1038/s41380-024-02875-0 (opens in new tab) Full text (opens in new tab) Mental health treatment Depression research Social connection Psilocybin therapy +1